The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15
Matsuyama, S.; Kawase, M.; Nao, N.; Shirato, K.; Ujike, M.; Kamitani, W.; Shimojima, M.; Fukushi, S.
Show abstract
Steroid compounds, which are expected to have dual functions in blocking host inflammation and MERS-CoV replication, were screened from a chemical library. Within this library, ciclesonide, an inhaled corticosteroid, suppressed human coronavirus replication in cultured cells, but did not suppress replication of respiratory syncytial virus or influenza virus. The effective concentration of ciclesonide to block SARS-CoV-2 (the cause of COVID-19) replication (EC90) was 6.3 M. After the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, which resulted in an amino acid substitution (A25V) in nonstructural protein (NSP) 15, as identified using reverse genetics. A recombinant virus with the mutation was also resistant to ciclesonide suppression of viral replication. These observations suggest that the effect of ciclesonide was specific to coronavirus, suggesting this is a candidate drug for treatment of patients suffering MERS or COVID-19.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity 96%
- Selective estrogen receptor modulators limit alphavirus infection by targeting the viral capping enzyme nsP1 94%
- Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants 94%
Similar papers in this journal
- The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral replication-transcription complex in culture cells 98%
- Inhibitors of anti-apoptotic Bcl-2 family proteins exhibit potent and broad-spectrum anti-mammarenavirus activity via cell cycle arrest at G0/G1 phase 95%
- Screening of Botanical Drugs Against Lassa Virus Entry 94%
Similar papers in this journal
- Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants. 95%
- Kite-shaped molecules block SARS-CoV-2 cell entry at a post-attachment step 94%
- Effect of exportin 1/XPO1 nuclear export pathway inhibition on coronavirus replication. 94%
Similar papers in this journal
- A vimentin-targeting oral compound with host-directed antiviral and anti-inflammatory actions addresses multiple features of COVID-19 and related diseases 93%
- Genome-wide characterization of SARS-CoV-2 cytopathogenic proteins in the search of antiviral targets 93%
- The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication 93%
Similar papers in this journal
- Post-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection 92%
- HSATII RNA is induced via a non-canonical ATM-regulated DNA-damage response pathway and facilitates tumor cell proliferation and movement 92%
- Prevention and Treatment of SHIVAD8 Infection in Rhesus Macaques by a Potent D-peptide HIV Entry Inhibitor 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.